1Kleiner DE, Tuuttila A, Karl T, et al. Stability analysis of latent and active 72 - kDa type Ⅳ collagenase: the role of tissue inhabitor of metalloproteinase-2 ( timp - 2 ) [ J ]. Biochemistry, 1993, 32 (6): 1583-1592.
2Liotta LA, Stetler WG. Tumor invastion and metastasis: an imbalance of positive and negative regulation [J]. Cancer Res (suppl), 1991, 51 (18): 5054-5059.
3Byeme GL, Tiebosch AT, Putten HW, et al. Basement membranes in cervical cancer: Relationship to pelvic lymph node metastisis and prognosis [J]. Gynecol Oncol, 1995,57 (3): 351-355.
4Lee E, Vanghan DE, Parikh SH, et al. Regulation of matrix metalloproteinases and plasminogen activator inhibitor- 1synthesis by plasminogen in culured human vascular smooth muscle cells [J]. CircRes, 1996, 78 (1): 44-49.
5Nomura H, Sato H, Seiki M, et al. Expression of membrane type matrix metalloproteinase in humen gastyic carcinomas[J]. Cancer Res, 1995, 55 (15): 3263-3266.
6Imrem S, Kohn DB, Shimada H, et al. Overexpression of tisue inhabitor of metalloproteinase - 2 by retroviral-mediated gene transfer in vivo tumor growth and invasion [J]. Cancer Res, 1996, 56 (13): 2891-2895.
7Grignon DJ, Sakr W, Toth M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP- 2) expression are associated with poor outcome in invasive bladder cancer [J].Cancer Res, 1996, 56 (7): 1654-1659.
8Narno S, Takigawa H, Takigawa H, et al. Serum levels of a tissue inhibitor of metalloproteinases - 1 ( TIMP - 1 ) in bladder cancer patients[J]. lnt JUrot, 1994,1(3) :228 - 231.
9Spiridione G, Giorgio S, Laura M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and respond to therapy [J]. Cancer Res, 1992, 52 (16): 4548- 4549.
10Peter BD, Bloxidge RE, Stuart NS, et al. Association between expression of activated 72 kilodalton gelatinase and tumor spread in non small lung cancer [J]. J Natl Cancer Inst,1993, 85 (7): 574-578.
2Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, plateletderived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis[J]. Cancer Res, 1997, 57(5): 963-969.
3Fang W, Hartmann N, Chow DT, et al. Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer[J]. J Biol Chem, 1992, 267(36): 25889-25897.
4Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer[J]. Cancer Lett, 2004, 204(2): 127- 143.
5Zhang N, Zhong R, Wang ZY, et al, Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant[J]. J Biol Chem, 1997, 272(27): 16733 - 16736.
6Shimizu M, Saitoh Y, Itoh H, et al. Immunohistochemical staining of Ha-ras ongene product in normal, benign, and malignant human pancreatic tissue[J]. Hum Pathol, 1990, 21 (6): 607-612.
7Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancerdcurrent status and future directions[J]. Ann Oncol, 2009, 20(12): 1913-1927.
8Rakha EA, E1-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
9Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype[J]. Clin Cancer Res, 2008, 14(5): 1368-1376.
10Perou CM, Sorlie T, Eisen M B, et al. Molecular portrait of human breast tumors[J]. Nature, 2000, 406(6797): 747-752.
